Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medication Management, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,014,025

1,460 payments

Through program year 2025, Medication Management, LLC is reported as receiving $1,014,025 in research payments, across 1,460 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $229,727 124
2024 Research $223,765 24
2023 Research $129,406 105
2022 Research $128,240 289
2021 Research $127,244 805
2020 Research $57,517 95
2019 Research $118,126 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $378,927 9 payments
  2. Novo Nordisk AS $165,239 1,015 payments
  3. Ironwood Pharmaceuticals, Inc $117,124 10 payments
  4. Boehringer Ingelheim International GmbH $78,392 116 payments
  5. Celgene Corporation $73,830 6 payments
  6. Urogen Pharma, Inc. $67,310 15 payments
  7. Abbott Laboratories $51,128 49 payments
  8. Masimo Corporation $42,169 7 payments
  9. Amgen Inc. $16,695 4 payments
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $14,724 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $376,959 5 payments
  2. C3718-301 $117,124 10 payments
  3. Nn1436-4477 $71,979 655 payments
  4. Urogen Pharma Bl010 $60,510 12 payments
  5. BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $48,538 4 payments
  6. Nn9536-4375 $46,867 14 payments
  7. Nn1436-4481 $45,722 343 payments
  8. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $41,525 112 payments
  9. Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $27,718 2 payments
  10. A Multi-Center, Multi-National, Randomized, Double - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects wit $23,335 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record